Tie Li's most recent trade in Aardvark Therapeutics Inc. was a trade of 203,851 Stock option (right to buy) done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 203,851 | 203,851 | - | - | Stock option (right to buy) | |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.48 per share. | 11 Dec 2025 | 7,000 | 1,551,613 | - | 14.5 | 101,395 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 1,229 | 40,566 | - | - | Stock option (right to buy) | |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.24 per share. | 15 Oct 2025 | 1,229 | 1,544,613 | - | 4.2 | 5,211 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.51 per share. | 15 Sep 2025 | 6,500 | 1,539,884 | - | 9.5 | 61,819 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.94 per share. | 15 Sep 2025 | 3,500 | 1,543,384 | - | 9.9 | 34,805 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.91 per share. | 10 Sep 2025 | 9,000 | 1,522,384 | - | 7.9 | 71,213 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.82 per share. | 10 Sep 2025 | 6,000 | 1,528,384 | - | 7.8 | 46,926 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.50 per share. | 10 Sep 2025 | 5,000 | 1,533,384 | - | 8.5 | 42,516 | Common Stock |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2025 | 17,209 | 41,795 | - | - | Stock option (right to buy) | |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.24 per share. | 28 Aug 2025 | 17,209 | 1,513,384 | - | 4.2 | 72,966 | Common Stock |
| Natures Miracle Holding Inc | Tie Li | Director, Chairman, CEO, and Director, Ten Percent Owner | Other type of transaction at price $ 0.13 per share. | 24 Jul 2025 | 5,160,739 | 5,592,580 | - | 0.1 | 673,476 | Common Stock |
| Natures Miracle Holding Inc | Tie Li | Director, Chairman, CEO, and Director, Ten Percent Owner | 24 Jul 2025 | 3,425,706 | 3,425,706 | - | 0.2 | 678,290 | Common Stock | |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 549,534 | 549,534 | - | - | Stock option (right to buy) | |
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | 14 Feb 2025 | 350,002 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | 14 Feb 2025 | 41,303 | 1,479,633 | - | - | Common Stock | ||
| Aardvark Therapeutics Inc | Tien-Li Lee | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 14 Feb 2025 | 16,542 | 1,496,175 | - | 16 | 264,672 | Common Stock |
| Finnovate Acq Corp (Class A) | Tiemei Li | Director | Other type of transaction at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 10,000 | - | 0 | Class A Ordinary Shares, par value $0.0001 per share | |
| Natures Miracle Holding Inc | Tie Li | Director, Chairman, CEO, and Director, Ten Percent Owner | Other type of transaction at price $ 0.09 per share. | 19 Nov 2024 | 6,562,500 | 12,955,248 | - | 0.1 | 577,500 | Common Stock |
| Scilex Holding Co | Tien-Li Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 250,000 | 250,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Singularity Future Tech Ltd | Tieliang Liu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 20,000 | 48,000 (0%) | 0% | 0 | Common Stock |